Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis

Mod Rheumatol. 2016;26(3):454-7. doi: 10.3109/14397595.2014.885377. Epub 2014 Mar 4.

Abstract

Systemic sclerosis (SSc) is characterized by disturbed blood circulation. The effect of ambrisentan, an endothelin-A receptor-selective antagonist, on impaired peripheral circulation in SSc remains largely elusive. Here we show SSc patients, whose clinical symptoms such as cyanosis and Raynaud's phenomenon, were ameliorated by the treatment with ambrisentan. Additionally, objective evaluations with thermography showed improvement of hand coldness in steady-state and cold challenge tests. Ambrisentan might have a potential to improve peripheral circulation in SSc.

Keywords: Ambrisentan; Cyanosis; Raynaud's phenomenon; Systemic sclerosis; Thermography.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Endothelin A Receptor Antagonists / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Phenylpropionates / therapeutic use*
  • Pyridazines / therapeutic use*
  • Raynaud Disease / drug therapy*
  • Scleroderma, Systemic / drug therapy*
  • Treatment Outcome

Substances

  • Endothelin A Receptor Antagonists
  • Phenylpropionates
  • Pyridazines
  • ambrisentan